U.S. Markets closed

Neurocrine Biosciences, Inc. (NBIX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
46.2200-2.42 (-4.99%)
At close: 4:00PM EDT

46.5962 0.38 (0.81%)
After hours: 4:47PM EDT

People also watch
ALKSPGNXLGNDNKTRINCY
  • 47.26 in March..... after approval of Ingrezza, few weeks after approval, today 5/26.. $47.16.... Happens all over Biotech.. SRPT 60 after conditional approval... now 30.
    I've had Nbix a long time and a fairly large position. Can't help but think of the market as a casino without the free drinks... hard to be an investor...... makes more sense to be a momentum player or flipper.
  • Doctor: Agree. P2 study problem is dosing issue. Not efficacy. Dosing needs tweaking. Nothing changed. Strong partnership (ABBV). Good balance sheet. Institutional support. Disruptive technology. Buy the dip. & Relax
  • One more quick point, the TS news was of course a disappointment, but let's not look past the potential for TD:

    Approx. 500,000 sufferers of TD in the US
    Approx. 350,000 of these are adults
    Approx. 10% of these suitable for the prescription of Ingrezza (according to a few physician interviews I have read)
    Approx. wholesale price of $50,000 (10% discount assunption from announced $64k)
    Approx. peak sales $1.75 billion

    We are not using outlandish assumptions here, the US opportunity alone is big. We are not even factoring in the Elagolix royalty, this could hit more than $0.5 billion, plus AbbVie does the marketing for us!
  • Surely an over reaction?

    Even if Ingrezza is only ever approved for TD we should be pricing higher than this.
  • When they released that PR saying that they were going to report data at the upcoming conference, I was sure this was in the bag - I even added a little at 52. Well...market is being fairly gentle about this after hours...that's encouraging. Also, I personally believe the explanation about dosing, and that this just needs a little tinkering to get right. I was really counting on this one, though. Biotech has been rough lately.
  • I read that article out today - found in the summary section - and learned something I didn't know. TD is currently controlled by benzodiazapines - xanax and the like - and ever-increasing doses have to be used.
    That is absolutely horrible. Benzos eventually turn into a total nightmare for many people using them long term - even under the strictest supervision. I've been through it and it's awful...they seem benign at first, but when you stop you can really be in trouble. It takes a long to get over them, and it's not pretty.
    This makes me feel even better about being invested in NBIX - Ingrezza is a major improvement for people already suffering.
    I started out in biotech by investing in Gilead, and pricing controversy aside, I was proud to be investing in a company eradicating a miserable disease. This is what makes biotech great.
  • still short, still covering at $40. rinse and repeat. lot closer to $40 after today!
  • Buy on the dip. They just need a big sister to teach them PK.
  • I'm still waiting to buy at $25.
  • Insiders made their money
  • Anyone know if the company has previously been linked with any sort of takeover?

    Has there ever been any rumours/links to acquirers floating around?
  • Houston we have a problem.
  • We might have green day today. Strong support around $48.
  • May has been a bad week for biotech, today is particularly atrocious due to politics...and we're still flirting around our 52-week high. Tourette's data is positive. I have no doubt.
  • Perhaps a short-term pull back is more likely before the next rally on NBIX? google aw-esomeSTOCKS - they offer pretty good trade alerrts. you dont have to trade their tickers but it definetly helps you recognize possible patterns for stocks you're trading.
  • How much will it pop if TS pediatric data is positive? Glta
  • What goes up must come down. I will buy at $25.
  • Wow, drop 8% after hour.
  • Politics effect, staying long, all the good news still ahead.
  • im Out